Amphetamine Stimulant denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny an Amphetamine Stimulant as Experimental — and How to Appeal

Amphetamine-based stimulants have longstanding FDA approval for ADHD and, in some formulations, for narcolepsy. A denial coded as "experimental" or "investigational" for this drug class is unusual and typically points to one of three situations: (1) the specific formulation or delivery mechanism is newer and UHC's coverage policy has not yet recognized it; (2) the prescribed indication falls outside the approved labeling (an off-label use); or (3) there is a documentation gap that caused the claim to be routed to experimental-review criteria instead of standard ADHD coverage criteria.

Because established amphetamine stimulants have a deep evidence base for their approved indications, this type of denial is often overturnable — particularly when the prescriber can clearly establish that the prescribed use falls within FDA-approved labeling or within recognized clinical-guideline organizations' recommendations.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): The plan must conduct a full-and-fair review, including all clinical criteria applied. You are entitled to receive every document the plan relied on to classify this treatment as experimental.
• External review (ACA §2719): Experimental-or-investigational denials are explicitly subject to external review under the ACA. An independent IRO applies objective medical standards — not UHC's internal coverage policy in isolation. File within the window in your denial letter (typically around 180 days from the final internal denial).
• Expedited review: Available for urgent clinical situations; response typically required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — Comprehensive evaluation records confirming the diagnosis for which the stimulant was prescribed. 2. FDA-labeling alignment letter — Your prescriber should confirm in writing that the prescribed use is consistent with the FDA-approved prescribing information, and attach or reference the relevant section of the approved labeling. 3. Clinical guideline organization support — Reference the applicable professional body (e.g., the American Academy of Pediatrics or American Psychiatric Association) recognizing stimulant therapy as a standard of care for the documented diagnosis — without citing specific statistics or score cutoffs. 4. Prior treatment history — Records of any prior stimulant trials that support the clinical context for this specific prescription. 5. Peer-reviewed literature — Your prescriber may attach published review articles supporting the use, without requiring you to assert specific trial statistics yourself.

## Criteria-Mapping Strategy

Request the specific UHC clinical coverage policy and the experimental-review criteria that were applied. Match every criterion against your chart documentation. If the denial was triggered by a newer formulation, confirm whether UHC has issued any coverage determination for that formulation and cite it. A clear side-by-side mapping — criterion, chart evidence, FDA or guideline alignment — is the most effective format for this appeal.